This episode launches a new SHBA series on drug pooling and why it matters to Canadian employers, advisors, carriers, and patients. Carolyne Eagan and Robin Bailey are joined by actuary Gary Walters, who explains how pooling was designed to protect small businesses from catastrophic claims and why that model is now under strain.
In this conversation, we discuss the gap between the original promise of predictability and today’s reality of higher-frequency, higher-cost specialty drug claims, rare disease therapies, and gene therapies. Gary also breaks down the two pooling layers, the communication gap employers face, and why solving this requires coordinated action across the entire ecosystem.
What You Will Learn:
- Why pooling charges have become a more visible and contentious part of renewals for small and midsize employers.
- How drug pooling was originally designed to protect small businesses from catastrophic claims.
- The difference between carrier internal pools and the CDIPSI industry pool.
- Why recurrent claims are shared across insurers.
- How small increases in claim size can lead to significant increases in pooled costs.
- Why specialty drugs, biologics, oncology therapies, rare disease treatments, and gene therapies are putting pressure on the existing model.
- Why employers often find pooling costs difficult to understand.
- How the current private pooling model may need to evolve to address ultra-high-cost and lifelong treatments.
- Why greater coordination among employers, advisors, carriers, government, and pharmaceutical manufacturers is essential.
- How the benefits industry can move beyond silos and work toward shared solutions.
Featuring:
- Carolyne Eagan, SHBA, Advocacy In Action Co-Host
- Robin Bailey, Aria Benefits, Advocacy in Action Co-Host
- Gary Walters, Chief Actuary at GroupHEALTH, Chair of the SHBA Board
Resources:
- How CDIPC Pooling Works (Advisor) – Canadian Drug Insurance Pooling Corporation
- FAQ (Advisor) – Canadian Drug Insurance Pooling Corporation
- Implementation Advisory Group (IAG) for the National Strategy for Drugs for Rare Diseases – Canada.ca
Bring Your Voice to the Table. Learn More about Membership with SHBA by clicking Here.
🎧 Follow and Listen to Advocacy In Action any time! YouTube | Spotify